Search the Site

Fully-human Monoclonal Antibodies Against Human EphrinB2 and EphB4

Keywords: Research Tools, Monoclonal Antibodies, Ephrin Receptor Tyrosine Kinases

Background: 
The Center for Cancer Research's Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fully-human monoclonal antibodies against human EphrinB2 and EphB4.

Description of Invention: 
Ephrin receptor tyrosine kinases and their ephrin ligands have been implicated in cancer pathogenesis. Ephrin receptors and ligands affect tumor growth, invasiveness, angiogenesis, and metastasis. Ephrin signaling activities in cancer are complex and are only now beginning to be uncovered.

Researchers at the National Cancer Institute-Frederick, NIH, have developed a set of five fully-human monoclonal antibodies against human Ephrin-B2 and Ephrin type-B receptor 4 ("EphB4"). The antibodies were identified by screening a naive human antibody phage display library against Ephrin-B2 and EphB4. These human monoclonal antibodies have high affinity and specificity for Ephrin-B2 and EphB4.

Applications:

• Research reagents for in vitro/in vivo investigation of Ephrin receptor and ligand interactions
• Targeting reagents for in vivo imaging
• Research reagents for protein co-crystallization

Advantages:

• High affinity and antigen specificity
• Bind both soluble ectodomains and cell surface-expressed molecules

Patent Status: 
Research Material.  Patent protection is not being pursued for this technology.
   
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov

Please reference advertisement #1036

Revised 4/7/2010

---

Opportunities available in PDF format require Adobe Reader to view.